Selina M. Luger, MD (IMAGE)

ECOG-ACRIN Cancer Research Group

Selina M. Luger, MD

Caption

"E1910 is the first randomized trial to demonstrate that we are able to improve the survival of adults with B-cell precursor acute lymphoblastic leukemia who are in complete remission, including by sensitive MRD testing, and establishes the addition of blinatumomab immunotherapy to standard consolidation chemotherapy as a treatment that will change clinical practice," said co-author Selina M. Luger MD, FRCPC (pictured). Dr. Luger is Chair of the ECOG-ACRIN Leukemia Committee and a Professor of Medicine at the University of Pennsylvania's Perelman School of Medicine and Abramson Cancer Center in Philadelphia.

Credit

ECOG-ACRIN

Usage Restrictions

No restrictions.

License

Public Domain

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.